Therapeutic Vaccination against HPV16 in HIV+ Men with anal dysplasia Therapeutische vaccinatie tegen HPV16 bij HIV-positieve mannen met anale dysplasie

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-005466-34

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The objective of the current proposal is to assess, in a phase 1/2 study, the safety and efficacy of a synthetic vaccine SLP-HPV-01® in HIV+ men with CD4 counts > 350 x 10E6/l and intra-anal high-grade, HPV16 positive AIN, who failed on previous treatment.


Critère d'inclusion

  • HPV16-induced intra-anal high-grade AIN (grade 2-3) in HIV+ men, that was resistant to, or recurred after conventional cauterization or other forms of local treatment

Liens